In the randomized phase 1b/2 Morpheus-Melanoma trial evaluating various neoadjuvant immune checkpoint inhibitor regimens in patients with resectable stage III melanoma, tobemstomig, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback